June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Prospective, randomized, subject-masked evaluation of intravitreal Sirolimus vs. anti-VEGF in chronic neovascular AMD with persistent retinal fluid: 1-year follow-up
Author Affiliations & Notes
  • Peter Bracha
    Ophthalmology, Indiana University, Indianapolis, Indiana, United States
  • Jay Chhablani
    L V Prasad Eye Institute, Smt. Kanuri Santhamma Retina Vitreous Centre, Hyderabad, India
  • Ashley Harless
    Ophthalmology, Midwest Eye Institute, Indianapolis, Indiana, United States
  • Sunila Dumpala
    L V Prasad Eye Institute, Smt. Kanuri Santhamma Retina Vitreous Centre, Hyderabad, India
  • Raj Maturi
    Ophthalmology, Midwest Eye Institute, Indianapolis, Indiana, United States
    Ophthalmology, Indiana University, Indianapolis, Indiana, United States
  • Footnotes
    Commercial Relationships   Peter Bracha, None; Jay Chhablani, None; Ashley Harless, None; Sunila Dumpala, None; Raj Maturi, Allegro (F), Allergan (C), Genentech (F), GlaxoSmithKline (F), Graybug Vision (C), Santen (F)
  • Footnotes
    Support  Supported by an investigator initiated grant from Santen
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 2967. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Peter Bracha, Jay Chhablani, Ashley Harless, Sunila Dumpala, Raj Maturi; Prospective, randomized, subject-masked evaluation of intravitreal Sirolimus vs. anti-VEGF in chronic neovascular AMD with persistent retinal fluid: 1-year follow-up. Invest. Ophthalmol. Vis. Sci. 2017;58(8):2967.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose :
To evaluate the safety and effectiveness of intravitreal Sirolimus in chronic and persistent exudative age-related macular degeneration (AMD).

Methods : In this prospective, subject-masked study, patients were randomized to monthly anti-vascular endothelial growth factor (anti-VEGF) treatment or to intravitreal Sirolimus (440 µg) at months 0, 2 and 4. Safety and effectiveness outcomes were measured monthly up to month six, with an extension to one year for patients who remained in the study. The primary outcome was the change in central subfield thickness and the secondary outcomes were the change in total subretinal fluid, total intraretinal fluid, choroidal neovascularization volume and visual acuity.

Results : The CST increased by 7.5 µm in the anti-VEGF group and decreased by 30.0 µm in the Sirolimus group at month six (p<0.05). On subgroup analysis for patients receiving Sirolimus, a trend towards greater reduction in the CST was found in patients with fewer prior injections, longer duration of disease and greater initial CST. The presence of IRF at baseline did not affect CST outcomes. In addition to the central subfield thickness, a statistically significant decrease in total subretinal fluid occurred in the Sirolimus group.

At six months, the number of patients who gained 5 or more Early Treatment of Diabetic Retinopathy Study (ETDRS) letters was 9 in each group (p=0.91). The number of patients who gained or lost less than 5 ETDRS letters was 11 in the anti-VEGF group and 7 in the Sirolimus group (p=0.40). The difference in the number of serious systemic or ocular adverse events between the two groups was not statistically different.

Conclusions : This study demonstrates Sirolimus as a promising new therapy for chronic and persistent exudative AMD. Sirolimus decreased the central subfield thickness and subretinal fluid more effectively than anti-VEGF agents and had a similar safety profile.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×